|
Media Releases |
Financial Reports |
Presen-tations |
|
04/29/2005
|
|
|
|
| Lonza expands its peptides capacity |
| Lonza announced today the initiation of a significant investment program in the expansion of its peptides manufacturing capacities in its production site in Visp, Switzerland. |
The investment totals about CHF 24 million (USD 20 million). By expanding its manufacturing activities Lonza is responding to the increased demand for peptide APIs worldwide and the increasing number of new entities entering clinical phase trials.
The investment is focused on several areas of Lonza's peptides and oligonucleotides (tides) large-scale cGMP manufacturing activities. To serve customers' demand for clinical trial material the construction of a new mid-scale tides plant is planned. Additional HPLC-purification and new lyophilization equipment as well as essential items of infrastructure will be installed.
With this investment Lonza - being the only peptide manufacturer able to use liquid- solid- and recombinant technology - underscores its strategic commitment to become the preferred supplier in this area.
Lonza is a life sciences driven company, headquartered in Switzerland, which generated sales of CHF 2.18 billion in 2004. It operates 18 production and R&D facilities in eight countries and employs 5670 people worldwide. Lonza is one of the leading custom manufacturers of chemical intermediates and active ingredients as well as biopharmaceuticals for the pharmaceutical and agrochemical industries. In addition, Lonza offers organic intermediates for a wide range of applications and provides antimicrobial and associated products as well as polymer intermediates and compounds. For more information please visit the company's website at www.lonza.com.
For further information please contact:
Media
Christine Menz
Tel +41 61 316 8253
Fax +41 61 316 9253
christine.menz@lonza.com
Investor Relations
Laura Gerber
Tel +41 61 316 83 47
Fax +41 61 316 82 20
laura.gerber@lonza.com
|
|
|
